4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 - Names and Identifiers
Name | A-317491
|
Synonyms | 3 2 A317491 A-317491 A 317491 A-317491 sodium 4-tricarboxylic acid SODIUM SALT HYDRATE 4-TRICARBOXYLIC ACID A-317491 DISODIUM SALT (S)-5-((3-phenoxybenzyl)(1 (S)-5-((3-PHENOXYBENZYL)(1 4-TETRAHYDRONAPHTHALEN-1-YL)CARBAMOYL)BENZENE-1 4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 (S)-5-((3-phenoxybenzyl)(1,2,3,4-tetrahydronaphthalen-1-yl)carbaMoyl)benzene-1,2,4-tricarboxylic acid 5-[[(3-Phenoxybenzyl)[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid
|
CAS | 475205-49-3
|
4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 - Physico-chemical Properties
Molecular Formula | C33H27NO8
|
Molar Mass | 565.57 |
Density | 1.46±0.1 g/cm3(Predicted) |
Boling Point | 840.4±65.0 °C(Predicted) |
Solubility | H2O: ~34mg/mL |
Appearance | powder |
Color | white |
pKa | 2.57±0.10(Predicted) |
Storage Condition | -20℃ |
In vitro study | A- 317491 effectively inhibited recombinant human and rat P2X3 and P2X2/3 receptor-mediated calcium flux (Ki = 22-92 nM), compared with other P2 receptors and neurotransmitter receptors, ion channels and enzymes (IC50 >10 M), with high selectivity for P2X3 and P2X2/3 receptors. No detectable metabolic processes (oxidation or glycolipidation) occurred in A- 317491 of human and rat hepatocyte microsomes in vitro. |
In vivo study | In rats, A- 317491(ED50=30 μmol/kg s.c.) was able to dose-dependently reduce CFA(complete Freund's adjuvant)-induced thermal hyperalgesia. Thermal hyperalgesia and mechanical hyperalgesia (ED50=10-15 μmol/kg s.c.) were effectively relieved by A- 317491 after chronic neuroconstriction injury. A- 317491 is active in chronic pain models, but in acute pain, postoperative pain, visceral pain, there was no nociceptive effect (ED50 >100 μmol/kg s.c.). Preliminary pharmacokinetic studies in rats showed high systemic bioavailability A- 317491 after subcutaneous injection of 10 μmol/kg A- 317491, plasma concentration is approximately 15 μg/ml,>99% protein binding, half-life in plasma is 11 hours. Systemic administration (A-317491) was effective in reducing pain-related behaviors in several animal models of inflammatory, neuropathic pain. A- 317491 was found not to be significantly involved in the central nervous system in the current study. |
4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 - Risk and Safety
4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 1.768 ml | 8.841 ml | 17.681 ml |
5 mM | 0.354 ml | 1.768 ml | 3.536 ml |
10 mM | 0.177 ml | 0.884 ml | 1.768 ml |
5 mM | 0.035 ml | 0.177 ml | 0.354 ml |
Last Update:2024-01-02 23:10:35
4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1 - Introduction
A- 317491 is an organic compound with the chemical name N-[4-(benzyl)-3-(2-(3-methylphenyl) ethoxy) phenyl] Formamide. It is a non-selective ATP-sensitive P2X3, P2X2/3 receptor antagonist.
A-317491 is mainly used to study the role of blocking P2X3 receptors in neurotransmitter signaling. It can be used in the treatment of chronic pain, inflammatory diseases and other related diseases.
A-317491 preparation method is more complex, generally take the organic synthesis method of synthesis. The specific preparation process can refer to the professional organic synthesis literature.
Regarding safety information, the specific toxicity and safety of A- 317491 have not been fully reported. During use, pay attention to safe operation, avoid direct contact with skin and inhalation of dust. It is recommended to use suitable personal protective equipment in the laboratory environment, such as laboratory gloves, protective glasses and laboratory ventilation equipment. Before use, please refer to the relevant safety data sheets and operating instructions. If you have any discomfort or other problems, please consult a professional in time.
Last Update:2024-04-09 20:02:46